Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Relmada Therapeutics, Inc. OTC Markets

Equities

RLMD

US75955J4022

Real-time Estimate Cboe BZX
Other stock markets
 10:36:55 17/07/2024 pm IST 		5-day change 1st Jan Change
3.67 USD 0.00% Intraday chart for Relmada Therapeutics, Inc. +8.91% +139.13%
01/07 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index CI
01/07 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index CI

Evolution of the average Target Price on Relmada Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ce06651b8bf15272b6c959ea3a7cbe17.XwKLS-1Ruc-oLn1fH4sNib8DV5tlaonxdzCib9Fw2Es.FVW-Hd4r9o7iZ0hqSrxZueV3IMQkBdvAAAPJA5wZ4Rtqd7gl3STQjMpvNA~ecd39c251ae97b1bb7518ffdba200750

Analyst Recommendations on Relmada Therapeutics, Inc.

Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target MT
SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating MT
Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target MT
Goldman Sachs Downgrades Relmada Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $81 MT
Guggenheim Downgrades Relmada Therapeutics to Neutral From Buy MT
Truist Securities Downgrades Relmada Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $90 MT
Oppenheimer Downgrades Relmada Therapeutics to Perform From Outperform, Adjusts Price Target to $7 From $64 MT
Goldman Sachs Adjusts Price Target on Relmada Therapeutics to $81 From $49, Reiterates Buy Rating MT
Guggenheim Adjusts Price Target on Relmada Therapeutics to $60 From $50, Reiterates Buy Rating MT
Goldman Sachs Adjusts Price Target for Relmada Therapeutics to $49 From $47, Maintains Buy Rating MT
Oppenheimer Adjusts Relmada Therapeutics' Price Target to $64 From $75, Maintains Outperform Rating MT
Goldman Sachs Adjusts Relmada Therapeutics' Price Target to $53 from $69, Keeps Buy Rating MT
SVB Leerink Adjusts Relmada Therapeutics' Price Target to $42 from $50, Keeps Outperform Rating MT
Mizuho Securities Starts Relmada Therapeutics at Buy With $50 Price Target MT
RELMADA THERAPEUTICS : Truist Securities Adjusts Relmada Therapeutics PT to $90 From $75, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.77 USD
Average target price
10.62 USD
Spread / Average Target
+181.83%
High Price Target
25 USD
Spread / Highest target
+563.13%
Low Price Target
2 USD
Spread / Lowest Target
-46.95%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Relmada Therapeutics, Inc.

Goldman Sachs
SVB Securities LLC
Oppenheimer
Guggenheim
Truist Securities
SVB Leerink
Mizuho Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. RLMD Stock
  5. Consensus Relmada Therapeutics, Inc.